A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
Introduction Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. Case presentation The patient...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12532 |
| _version_ | 1811333403423801344 |
|---|---|
| author | Hiroyuki Fukunaga Kenta Sumii Shun Kawamura Masato Okuno Isao Taguchi Gaku Kawabata |
| author_facet | Hiroyuki Fukunaga Kenta Sumii Shun Kawamura Masato Okuno Isao Taguchi Gaku Kawabata |
| author_sort | Hiroyuki Fukunaga |
| collection | DOAJ |
| description | Introduction Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. Case presentation The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. Conclusion A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event. |
| first_indexed | 2024-04-13T16:52:04Z |
| format | Article |
| id | doaj.art-6daab427aa6342679eec83e61d6d0ff7 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-04-13T16:52:04Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-6daab427aa6342679eec83e61d6d0ff72022-12-22T02:38:55ZengWileyIJU Case Reports2577-171X2022-11-015652152310.1002/iju5.12532A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximabHiroyuki Fukunaga0Kenta Sumii1Shun Kawamura2Masato Okuno3Isao Taguchi4Gaku Kawabata5Department of Urology Kansai Rosai Hospital Amagasaki‐shi JapanDepartment of Urology Kansai Rosai Hospital Amagasaki‐shi JapanDepartment of Urology Kansai Rosai Hospital Amagasaki‐shi JapanDepartment of Urology Kansai Rosai Hospital Amagasaki‐shi JapanDepartment of Urology Kansai Rosai Hospital Amagasaki‐shi JapanDepartment of Urology Kansai Rosai Hospital Amagasaki‐shi JapanIntroduction Immune checkpoint inhibitors are widely used in various cancers as a standard treatment. However, while various immune‐related adverse events related to immune checkpoint inhibitors have been reported, there are few reports of lower urinary tract symptoms. Case presentation The patient was a 60‐year‐old man with primary lung cancer who was receiving long‐term nivolumab therapy. He was referred to our department due to the sudden onset of glans penile pain and micturition pain. We suspected non‐bacterial cystitis as an immune‐related adverse event caused by nivolumab and were able to treat it by administering prednisolone. While his symptoms and findings on cystoscopy recurred during prednisolone therapy, we were able to treat him again by administering an additional dose of infliximab. Conclusion A few reports have described cases of immune checkpoint inhibitor‐induced cystitis for which prednisolone was effective. This report is the first to describe cystitis as a steroid‐resistant immune‐related adverse event.https://doi.org/10.1002/iju5.12532cystitisimmune checkpoint inhibitorsimmune related adverse eventinfliximabsteroid‐resistant |
| spellingShingle | Hiroyuki Fukunaga Kenta Sumii Shun Kawamura Masato Okuno Isao Taguchi Gaku Kawabata A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab IJU Case Reports cystitis immune checkpoint inhibitors immune related adverse event infliximab steroid‐resistant |
| title | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_full | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_fullStr | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_full_unstemmed | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_short | A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab |
| title_sort | case of steroid resistant cystitis as an immune related adverse event during treatment with nivolumab for lung cancer which was successfully treated with infliximab |
| topic | cystitis immune checkpoint inhibitors immune related adverse event infliximab steroid‐resistant |
| url | https://doi.org/10.1002/iju5.12532 |
| work_keys_str_mv | AT hiroyukifukunaga acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kentasumii acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT shunkawamura acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT masatookuno acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT isaotaguchi acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT gakukawabata acaseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT hiroyukifukunaga caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT kentasumii caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT shunkawamura caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT masatookuno caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT isaotaguchi caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab AT gakukawabata caseofsteroidresistantcystitisasanimmunerelatedadverseeventduringtreatmentwithnivolumabforlungcancerwhichwassuccessfullytreatedwithinfliximab |